API | oxyphenonium

oxyphenonium (antrenyl) Report issue

Small molecule Approved ^FDA

ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW

Oxyphenonium bromide is a quaternary ammonium anticholinergic agent, which was used under brand name antrenyl, to relieve visceral spasms and as an adjunct in the treatment of peptic ulcer. In addition, Oxyphenonium inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions. Action is achieved via a dual mechanism: a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and a direct effect upon smooth muscle. Oxyphenonium bromide also been used in the form of eye drops for mydriatic effec ^NCATS

Chemistry

SMILES: CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c2ccccc2
InChIKey: GFRUPHOKLBPHTQ-UHFFFAOYSA-N
Mol. Mass: 348.51
ALogP: 3.48 Partition coefficient
ChEMBL Molecules:

oxyphenonium

oxyphenonium bromide

More Chemistry

Pharmacology

Mechanisms of Action:
- Muscarinic acetylcholine receptor M1 (Homo sapiens) ^UniProt
- Muscarinic acetylcholine receptor M3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Discontinued
Delivery Methods: Oral
Pro Drug: No

antrenyl | oxyphenonium | oxyphenonium bromide | oxyphenonium cation | oxyphenonium ion

Organizations (2)

Research & Development (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (2)

Peptic Ulcer

Visceral Pain

Experimental Indications - Clinical Trial Phases 1-4 (1)

Mydriasis ()

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue